

Date: October 29–30, 2007.

Time: 8 a.m. to 9 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. (Virtual Meeting).

Contact Person: Malgorzata Klosek, PhD, Scientific Review Administrator, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4188, MSC 7849, Bethesda, MD 20892, 301–435–2211, Klosekm@csr.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: October 2, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–4991 Filed 10–9–07; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Center for Scientific Review; Amended Notice Meeting

Notice is hereby given of a change in the meeting of the Pathobiology of Kidney Disease Study Section, October 11, 2007, 8 a.m. to October 12, 2007, 5 p.m., Hotel Rouge, 1315 16th Street, NW., Washington, DC 20036 which was published in the **Federal Register** on September 21, 2007, 72 FR 54051–54054.

The meeting will be held one day only—October 11, 2007, 8 a.m. to 6 p.m. The meeting location remains the same. The meeting is closed to the public.

Dated: October 2, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–4993 Filed 10–9–07; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Allergy and Infectious Diseases, Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial information such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel.

Date: November 6, 2007.

Time: 1 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge 6700, 6700B Rockledge Drive, Bethesda, MD 20817. (Telephone Conference Call).

Contact Person: Paul A. Amstad, Ph.D., Scientific Review Administrator, Scientific Review Program, Division of Extramural Activities, DHHS/National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–402–7098, pamstad@niaid.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS).

Dated: October 3, 2007.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 07–4990 Filed 10–9–07; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Statement of Organization, Functions, and Delegations of Authority

Part N, National Institutes of Health (NIH), of the Statement of Organization, Functions, and Delegations of Authority for the Department of Health and Human Services (DHHS) (40 FR 22859, May 27, 1975, as amended most recently at 71 FR 1446, January 9, 2006, and redesignated from Part HN as Part N at 60 FR 56605, November 9, 1995), is amended as set forth below to reflect the transfer of the bioengineering and physical science functions from the Office of the Director, Office of Management, Office of Research Services (NAM5, formerly HNAM5), to the National Institute of Biomedical Imaging and Bioengineering (N8, formerly HN8).

Section N–B, *Organization and Functions*, is amended by replacing the current section N86 (formerly HN86) with the following:

Intramural Research Programs (N86, formerly HN86). Responsible for all aspects of NIBIB intramural research, including staffing, facilities, and research programs. Also includes the Laboratory of Bioengineering and Physical Science, which contributes to the advancement of NIH research by the application of engineering, mathematics, and the physical sciences to the solution of problems in biology and medicine through (1) consultations and collaborative research with NIH intramural scientists in the areas of measurement, imaging, mathematical analysis, and modeling and the design of specialized research protocols and equipment; (2) proposing and developing theoretical and experimental methods, including novel instrumentation, to meet long-term needs of the NIH Intramural Research Program; and (3) serving as a liaison to other NIH and non-NIH organizations with bioengineering and physical science expertise to obtain and disseminate information on technological resources and development applicable to NIH intramural research problems.

Section N–B, *Organization and Functions*, under the heading “Office of Research Services (NAM5, formerly HNAM5)” is amended as follows:

Delete the “Division of Bioengineering and Physical Science (NAM58, formerly HNAM58)” in its entirety.

Delegations of Authority Statement: All delegations and redelegations of authority to officers and employees of NIH that were in effect immediately prior to the effective date of this reorganization and are consistent with this reorganization shall continue in effect in them or their successors, pending further redelegation.

Dated: September 28, 2007.

Raynard S. Kington,

Acting Director, National Institutes of Health.

[FR Doc. E7–19933 Filed 10–9–07; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Devices for Countercurrent Chromatography

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive worldwide license to practice the invention embodied in: HHS Ref. No. E-321-2007 "Second Generation Improved Spiral Tube Support for Countercurrent Chromatography" to CC Biotech LLC, a company incorporated under the laws of the State of Maryland having its headquarters in Rockville, Maryland. The United States of America


is the assignee of the rights of the above inventions. The contemplated exclusive license may be granted in a field of use limited to devices and components for centrifugal or countercurrent chromatographic purification, isolation, or preparation of biomolecules and macromolecules.

DATES: Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before December 10, 2007 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed

to: Michael A. Shmilovich, Esq., Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-5019; Facsimile: (301) 402-0220; E-mail: shmilovm@mail.nih.gov. A signed confidentiality nondisclosure agreement will be required to receive copies of any patent applications that have not been published by the United States Patent and Trademark Office or the World Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: The patents and patent applications intended for licensure disclose or cover the following:



The support compactly holds spirally wound plastic tubing at a desired spiral pitch without connection. When mounted on the existing high-speed countercurrent chromatographic centrifuge, it will produce separation of bioactive compounds including proteins, nucleic acids, polysaccharides, and small molecular weight compounds from natural products without loss of samples in the separation column.

The present invention is an improvement on a spiral disc previously reported under E-014-2003 (now abandoned) which was published as WO 2004/085020. That disc differed in that the prior version the radial channels represented in the figure on the right (e.g., I1-O4; I4-O3, etc.) went all the way through the disc and ended at the outer wall and the center, thereby creating a channel that forced tubing to wrap around the device to re-enter the spiral grooves. Here, the direction of the tubing through the interleaved spiral grooves is continuous and the transition points between grooves are smoother. The design effectively eliminates about 5 cm of "dead-space," and allows for

the plates to be stackable; which was impossible with the previous design.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within sixty (60) days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: October 1, 2007.

Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7-19941 Filed 10-9-07; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Proposed Candidate Conservation Agreement With Assurances for Fisher for the Stirling Management Area, Sierra Pacific Industries, Butte, Plumas, and Tehama Counties, CA

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of availability; receipt of application.

SUMMARY: Sierra Pacific Industries (Applicant) has applied to the U.S. Fish and Wildlife Service (Service) for a 20-year enhancement of survival permit for the fisher (*Martes pennanti*) pursuant to section 10(a)(1)(A) of the Endangered